Literature DB >> 23190299

Mucosal healing and mortality in coeliac disease.

B Lebwohl1, F Granath, A Ekbom, S M Montgomery, J A Murray, A Rubio-Tapia, P H R Green, J F Ludvigsson.   

Abstract

BACKGROUND: Coeliac disease (CD), characterised by the presence of villous atrophy (VA) in the small intestine, is associated with increased mortality, but it is unknown if mortality is influenced by mucosal recovery. AIMS: To determine whether persistent VA is associated with mortality in CD.
METHODS: Through biopsy reports from all pathology departments (n = 28) in Sweden, we identified 7648 individuals with CD (defined as VA) who had undergone a follow-up biopsy within 5 years following diagnosis. We used Cox regression to examine mortality according to follow-up biopsy.
RESULTS: The mean age of CD diagnosis was 28.4; 63% were female; and the median follow-up after diagnosis was 11.5 years. The overall mortality rate of patients who underwent follow-up biopsy was lower than that of those who did not undergo follow-up biopsy (Hazard Ratio 0.88, 95% CI: 0.80-0.96). Of the 7648 patients who underwent follow-up biopsy, persistent VA was present in 3317 (43%). There were 606 (8%) deaths. Patients with persistent VA were not at increased risk of death compared with those with mucosal healing (HR: 1.01; 95% CI: 0.86-1.19). Mortality was not increased in children with persistent VA (HR: 1.09 95% CI: 0.37-3.16) or adults (HR 1.00 95% CI: 0.85-1.18), including adults older than age 50 years (HR: 0.96 95% CI: 0.80-1.14).
CONCLUSIONS: Persistent villous atrophy is not associated with increased mortality in coeliac disease. While a follow-up biopsy will allow detection of refractory disease in symptomatic patients, in the select population of patients who undergo repeat biopsy, persistent villous atrophy is not useful in predicting future mortality.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23190299      PMCID: PMC3566869          DOI: 10.1111/apt.12164

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  34 in total

Review 1.  The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review.

Authors:  Catherine Dubé; Alaa Rostom; Richmond Sy; Ann Cranney; Navaaz Saloojee; Chantelle Garritty; Margaret Sampson; Li Zhang; Fatemeh Yazdi; Vasil Mamaladze; Irene Pan; Joanne Macneil; David Mack; Dilip Patel; David Moher
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

Review 2.  Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue').

Authors:  M N Marsh
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

Review 3.  American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease.

Authors:  Alaa Rostom; Joseph A Murray; Martin F Kagnoff
Journal:  Gastroenterology       Date:  2006-12       Impact factor: 22.682

Review 4.  Celiac disease.

Authors:  Peter H R Green; Christophe Cellier
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

5.  How do Swedish paediatric clinics diagnose coeliac disease? Results of a nationwide questionnaire study.

Authors:  Lars Stenhammar; Lotta Högberg; Lars Danielsson; Henry Ascher; Anders Dannaeus; Olle Hernell; Anneli Ivarsson; Eva Lindberg; Bo Lindquist; Kerstin Nivenius
Journal:  Acta Paediatr       Date:  2006-11       Impact factor: 2.299

Review 6.  The diagnostic accuracy of serologic tests for celiac disease: a systematic review.

Authors:  Alaa Rostom; Catherine Dubé; Ann Cranney; Navaaz Saloojee; Richmond Sy; Chantelle Garritty; Margaret Sampson; Li Zhang; Fatemeh Yazdi; Vasil Mamaladze; Irene Pan; Joanne MacNeil; David Mack; Dilip Patel; David Moher
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

7.  Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy.

Authors:  M Tio; M R Cox; G D Eslick
Journal:  Aliment Pharmacol Ther       Date:  2012-01-13       Impact factor: 8.171

8.  Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease.

Authors:  K Kaukinen; M Peräaho; K Lindfors; J Partanen; N Woolley; P Pikkarainen; A-L Karvonen; T Laasanen; H Sievänen; M Mäki; P Collin
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

9.  Coeliac disease: a histological follow-up study.

Authors:  M T Bardella; P Velio; B M Cesana; L Prampolini; G Casella; C Di Bella; A Lanzini; M Gambarotti; G Bassotti; V Villanacci
Journal:  Histopathology       Date:  2007-03       Impact factor: 5.087

10.  Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet.

Authors:  Jacques Cosnes; Christophe Cellier; Sheila Viola; Jean-Frederic Colombel; Laurent Michaud; Jacques Sarles; Jean-Pierre Hugot; Jean-Louis Ginies; Alain Dabadie; Olivier Mouterde; Matthieu Allez; Isabelle Nion-Larmurier
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02-06       Impact factor: 11.382

View more
  38 in total

Review 1.  Advances in diagnosis and management of celiac disease.

Authors:  Ciarán P Kelly; Julio C Bai; Edwin Liu; Daniel A Leffler
Journal:  Gastroenterology       Date:  2015-02-03       Impact factor: 22.682

2.  Predictors and Significance of Incomplete Mucosal Recovery in Celiac Disease After 1 Year on a Gluten-Free Diet.

Authors:  Henna Pekki; Kalle Kurppa; Markku Mäki; Heini Huhtala; Harri Sievänen; Kaija Laurila; Pekka Collin; Katri Kaukinen
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 3.  (Outcome) Measure for (Intervention) Measures: A Guide to Choosing the Appropriate Noninvasive Clinical Outcome Measure for Intervention Studies in Celiac Disease.

Authors:  Prashant Singh; Jocelyn A Silvester; Daniel Leffler
Journal:  Gastroenterol Clin North Am       Date:  2018-12-13       Impact factor: 3.806

Review 4.  Coeliac disease and the videocapsule: what have we learned till now.

Authors:  Edward J Ciaccio; Suzanne K Lewis; Govind Bhagat; Peter H Green
Journal:  Ann Transl Med       Date:  2017-05

Review 5.  Current Status of Celiac Disease Drug Development.

Authors:  Manida Wungjiranirun; Ciaran P Kelly; Daniel A Leffler
Journal:  Am J Gastroenterol       Date:  2016-03-29       Impact factor: 10.864

6.  Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.

Authors:  Daniel A Leffler; Ciaran P Kelly; Peter H R Green; Richard N Fedorak; Anthony DiMarino; Wendy Perrow; Henrik Rasmussen; Chao Wang; Premysl Bercik; Natalie M Bachir; Joseph A Murray
Journal:  Gastroenterology       Date:  2015-02-13       Impact factor: 22.682

Review 7.  Serum markers in the clinical management of celiac disease.

Authors:  Marlou Adriaanse; Daniel A Leffler
Journal:  Dig Dis       Date:  2015-04-22       Impact factor: 2.404

Review 8.  The gluten-free diet and its current application in coeliac disease and dermatitis herpetiformis.

Authors:  Carolina Ciacci; Paul Ciclitira; Marios Hadjivassiliou; Katri Kaukinen; Jonas F Ludvigsson; Norma McGough; David S Sanders; Jeremy Woodward; Jonathan N Leonard; Gillian L Swift
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

9.  Persistent mucosal damage and risk of fracture in celiac disease.

Authors:  Benjamin Lebwohl; Karl Michaëlsson; Peter H R Green; Jonas F Ludvigsson
Journal:  J Clin Endocrinol Metab       Date:  2014-01-16       Impact factor: 5.958

10.  Predictors of persistent villous atrophy in coeliac disease: a population-based study.

Authors:  B Lebwohl; J A Murray; A Rubio-Tapia; P H R Green; J F Ludvigsson
Journal:  Aliment Pharmacol Ther       Date:  2014-01-16       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.